Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Alzheimer Disease

Could a newly discovered brain cell structure hold the secret to slowing Alzheimer's disease progression? Scientists uncover a hidden gatekeeper with shocking implications

Penn State scientists discovered a hidden structure within brain cells. This structure acts as a gatekeeper controlling what enters neurons. It regulates nutrient and protein uptake, which is vital for brain health. Disrupting this structure accelerates the absorption of harmful proteins linked to Alzheimer's. Preserving this cellular gatekeeper may offer…

The Economic Times

'Miracle on the Hudson' Hero Chesley 'Sulley' Sullenberger Reveals Alzheimer's Diagnosis: Here's What Early Symptoms Can Look Like

"Miracle on the Hudson" hero Chesley "Sully" Sullenberger has revealed he has early-stage Alzheimer's disease. His diagnosis is drawing attention to the condition's early symptoms and the importance of recognizing them promptly.

Medical Daily

New Alzheimer’s blood test to be trialled to speed up diagnosis – find out where

The aim is for up to 500 patients to be referred for a test, making it the largest UK study of Alzheimer’s blood tests in general practice

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

‘Landmark’ study to offer blood test for Alzheimer’s through GPs

Dementia affects about 90,000 people in Scotland, an estimated 3,000 of whom are aged under 65.

Evening Standard

Scientists Found That the Alzheimer's Protein Tau Is Also Essential for Normal Memory Formation

Flinders University researchers found in Nature Communications that tau — the Alzheimer's protein — is also essential for forming long-term memories in healthy brains via engram cell coordination.

Medical Daily

Paul Gambaccini reveals devastating Alzheimer's diagnosis

The veteran broadcaster has announced he is living with Alzheimer’s disease and says he plans to continue presenting his radio programmes while receiving support from the Alzheimer’s Society.

BANG Premier

Scientists Found Why Some Brains Resist Alzheimer's Disease: Here Is the Cellular Survival Mechanism They Discovered

Netherlands Institute for Neuroscience researchers found immature neuron behavior — not just quantity — determines Alzheimer's cognitive resilience. Here's what it means for the 30% who never develop dementia.

Medical Daily

Read news from The Economist, FT, and more,
with one subscription

New FDA-Approved Blood Tests Can Detect Alzheimer's Before Symptoms Worsen, but Access Remains Limited

Two FDA-approved blood tests can now detect Alzheimer's early, but Medicare doesn't cover pre-symptom screening and access gaps remain severe. Here's what you need to know.

Medical Daily

Scientists Just Reprogrammed Brain Immune Cells to Fight Alzheimer's Plaques and the Memory Results Are Striking

A June 19, 2026 study in Cell Death & Disease found molecule OLE reprograms microglia to contain amyloid plaques, reducing toxicity and improving memory in Alzheimer's models.

Medical Daily

Yoga may boost cognition, reduce depression, aid gut health in early Alzheimer's: AIIMS study

A 12-week yoga program has shown promising results for individuals with mild Alzheimer's disease. Researchers at AIIMS, Delhi, observed significant improvements in cognitive function and mood, alongside a healthier gut microbiome. The study suggests yoga may help restore beneficial gut bacteria, potentially influencing the gut-brain axis and offering a valuable…

The Economic Times

University of Florida Study Warns Glucosamine Users After Finding Link to 25% Faster Alzheimer's Disease Progression

University of Florida study in Nature Metabolism, June 9, 2026: glucosamine use linked to 25% faster MCI-to-Alzheimer's progression. What elderly supplement users need to know.

Medical Daily

Copper Compound Cu(ATSM) Cleared 42% of Alzheimer's Toxic Proteins and Restored Memory in Lab — ACS Chemical Neuroscience June 2026

Monash University: Cu(ATSM) increased brain's P-gp pumps 24%, cut amyloid-beta 42%, improved spatial memory 44% in Alzheimer's models. ACS Chemical Neuroscience, June 15, 2026.

Medical Daily

Alzheimer's Disease Is No Longer Untreatable: A 2026 Guide to the Blood Tests, Drugs, and Prevention Strategies That Are Changing the Future for 7 Million Americans

A comprehensive June 2026 guide to Alzheimer's prevention and treatment: two FDA-approved disease-modifying drugs (lecanemab/Leqembi, donanemab/Kisunla), an FDA-cleared blood test (Lumipulse pTau217), and the lifestyle interventions with the strongest prevention evidence.

Medical Daily

Magic mushrooms and Alzheimer’s: what one remarkable case can tell us

Magic mushrooms are better known for producing hallucinations and altering people’s sense of reality than for treating brain diseases. Most people associate them with tripping, rather than Alzheimer’s disease.

The Conversation

Get all your
news in one place.

100's of premium titles.
One news app.

Medical Daily

A Blood Test That Detects Alzheimer's Disease Years Before Brain Scans Can Just Took a Major Leap Forward — Harvard Study Confirms It Outperforms PET Imaging in Early Detection

Harvard Mass General Brigham study in Nature Communications (April 2026): plasma pTau217 blood test detects Alzheimer's progression years before PET scans. FDA already cleared Lumipulse pTau217 test for symptomatic patients.

Medical Daily

Alzheimer's Treatment Is Entering a New Era — Here Is Everything That Has Changed in 2026

Leqembi and Kisunla are slowing Alzheimer's decline by 27-35% in early-stage patients. The 2026 drug pipeline has 158 candidates in 192 trials. Prevention trials are beginning. Here's the full update.

The Conversation

Glucosamine supplements may speed memory loss from Alzheimer’s, new research shows

People with Alzheimer’s disease who took the common supplement glucosamine were 25% more likely to die within five years than those who didn’t. That’s the key finding of a new study that my colleagues and I published in the journal Nature Metabolism.

MarketBeat

Axsome Therapeutics Readies Auvelity Alzheimer’s Agitation Launch, Expands CNS Pipeline

Axsome Therapeutics (NASDAQ:AXSM) executives said the company is preparing to launch Auvelity in Alzheimer’s disease agitation this month while continuing to expand the drug’s use in major depressive disorder and advance a broad central nervous system pipeline. Speaking at a Jefferies fireside chat

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Air pollution could be affecting your brain power

The impacts are similar to what researchers would expect from 10 years of normal aging

AAP

Blood test could detect Alzheimer's 'decades before'

Using blood tests to pinpoint changes in the brain "could be incredibly valuable" for the early detection of Alzheimer's disease, researchers say.

The Independent UK

How a simple blood test could spot signs of Alzheimer’s ‘decades before symptoms’

A simple blood test may be able to spot signs of Alzheimer’s disease long before someone shows symptoms, a new study has revealed

Evening Standard

Blood test could detect signs of Alzheimer’s ‘decades before symptoms’ – study

The findings show that Alzheimer’s may be present in midlife and already linked to cognitive differences, researchers said.

Saving Advice

The ‘Sweet’ Habit Researchers Say Could Raise Your Alzheimer’s Risk

Many people think of sugary snacks as harmless comfort foods, especially during stressful days or late-night cravings. However, growing research suggests that regularly consuming large...

The Conversation

Blood biomarkers could detect earliest signs of Alzheimer’s disease – and slow its progression

Alzheimer’s disease, a progressive neurodegenerative disorder that affects millions worldwide, has a long preclinical stage. It potentially begins decades before clinical symptoms become apparent.

MarketBeat

ACADIA Pharmaceuticals Spotlights Alzheimer’s Psychosis Pipeline, NUPLAZID and DAYBUE Growth

ACADIA Pharmaceuticals (NASDAQ:ACAD) executives used an RBC Capital Markets investor session to outline the company’s clinical rationale for remlifanserin in Alzheimer’s disease psychosis, provide updates on commercial trends for NUPLAZID and DAYBUE, and discuss selected pipeline and business develo

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Alzheimer Research UK

156 stories

University of Florida

Nature Communications

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.